Amgen, Pfizer, abortion capsule, GSK: Readout E-newsletter
Wish to keep on high of the science and politics driving biotech at present? Join to get our biotech e-newsletter in your inbox.
Hullo! At this time, we speak about Amgen’s constructive new PCSK9 information, study extra concerning the new NIH workplace meant to cut back reliance on animal testing, and extra.
Amgen’s Repatha trial reveals coronary heart danger discount
Amgen stated yesterday that its cholesterol-lowering injection Repatha lower the danger of a composite of coronary heart illness demise, coronary heart assaults, and strokes in a 12,000-patient trial, bolstering hopes for wider use of PCSK9 inhibitors after years of sluggish adoption, STAT’s Matt Herper writes.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
